JIUYUAN GENE Sets 19 August Board Meeting to Approve 1H 2026 Results and Review Interim Dividend

Bulletin Express

Aug 10

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) will convene its Board of Directors on 19 August 2026 in Hangzhou to deliberate on several key matters related to the company’s mid-year performance.

The agenda includes: 1. Examination and approval of the consolidated interim results for the six months ended 30 June 2026. 2. Authorisation of the public release of the interim report. 3. Consideration of a potential interim dividend distribution to shareholders.

The meeting will be chaired by Executive Director and General Manager Mr. Fu Hang. The current Board comprises 12 members, including executive, non-executive, independent non-executive and employee-representative directors, ensuring broad oversight and governance as the company reviews its half-year financials.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1112118230"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112118230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112118230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112118230","market":"us","top_or_hot":-1,"title":"JIUYUAN GENE Sets 19 August Board Meeting to Approve 1H 2026 Results and Review Interim Dividend","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) will convene its Board of Directors on 19 August 2026 in Hangzhou to deliberate on several key matters related to the company’s mid-year performance.</p>\n<p>The agenda includes:  \n1. Examination and approval of the consolidated interim results for the six months ended 30 June 2026.  \n2. Authorisation of the public release of the interim report.  \n3. Consideration of a potential interim dividend distribution to shareholders.</p>\n<p>The meeting will be chaired by Executive Director and General Manager Mr. Fu Hang. The current Board comprises 12 members, including executive, non-executive, independent non-executive and employee-representative directors, ensuring broad oversight and governance as the company reviews its half-year financials.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JIUYUAN GENE Sets 19 August Board Meeting to Approve 1H 2026 Results and Review Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJIUYUAN GENE Sets 19 August Board Meeting to Approve 1H 2026 Results and Review Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-10 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) will convene its Board of Directors on 19 August 2026 in Hangzhou to deliberate on several key matters related to the company’s mid-year performance.</p>\n<p>The agenda includes:  \n1. Examination and approval of the consolidated interim results for the six months ended 30 June 2026.  \n2. Authorisation of the public release of the interim report.  \n3. Consideration of a potential interim dividend distribution to shareholders.</p>\n<p>The meeting will be chaired by Executive Director and General Manager Mr. Fu Hang. The current Board comprises 12 members, including executive, non-executive, independent non-executive and employee-representative directors, ensuring broad oversight and governance as the company reviews its half-year financials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1112118230","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112118230","pubTimestamp":1786363353,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) will convene its Board of Directors on 19 August 2026 in Hangzhou to deliberate on several key matters related to the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"九元基因定于 8 月 19 日召开董事会会议，批准 2026 年上半年业绩并审查中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) will convene its Board of Directors on 19 August 2026 in Hangzhou to deliberate on several key matters related to the company’s mid-year performance.\nThe agenda includes:  \n1. Examination and approval of the consolidated interim results for the six months ended 30 June 2026.  \n2. Authorisation of the public release of the interim report.  \n3. Consideration of a potential interim dividend distribution to shareholders.\nThe meeting will be chaired by Executive Director and General Manager Mr. Fu Hang. The current Board comprises 12 members, including executive, non-executive, independent non-executive and employee-representative directors, ensuring broad oversight and governance as the company reviews its half-year financials.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}